IONSHealthcare · BiotechnologyThe 25 Wall Street analysts covering Ionis Pharmaceuticals, Inc. hold a median 12-month price target of $85 — +111.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Ionis Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (89): The share price has been relatively steady.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on IONS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +111.9% from it.
Of the 20 most recent actions, 2 moved their price target up and 8 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | BMO Capital | Upgrade | Outperform | $54 → $66 |
| 15 Oct 2026 | UBS | Upgrade | Buy | $46 → $88 |
| 24 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $100 |
| 24 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Sept 2026 | JP Morgan | Maintains | Overweight | $76 → $70 |
| 22 Sept 2026 | JP Morgan | Maintains | Overweight | — |
| 15 Sept 2026 | Guggenheim | Maintains | Buy | $89 → $80 |
| 15 Sept 2026 | Guggenheim | Maintains | Buy | — |
| 9 Sept 2026 | Barclays | Maintains | Overweight | $90 → $85 |
| 9 Sept 2026 | Barclays | Maintains | Overweight | — |
| 8 Sept 2026 | BMO Capital | Maintains | Market Perform | — |
| 8 Sept 2026 | BMO Capital | Maintains | Market Perform | $61 → $54 |
| 8 Sept 2026 | Canaccord Genuity | Maintains | Buy | $95 → $85 |
| 8 Sept 2026 | Canaccord Genuity | Maintains | Buy | — |
| 8 Sept 2026 | Goldman Sachs | Maintains | Neutral | $69 → $56 |
| 8 Sept 2026 | Goldman Sachs | Maintains | Neutral | — |
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $115 → $100 |
| 8 Sept 2026 | Morgan Stanley | Maintains | Overweight | $110 → $104 |
| 8 Sept 2026 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IONS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Ionis Pharmaceuticals, Inc. returned −45.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 16% of US stocks
Cheaper than 6% of US stocks
Cheaper than 87% of US stocks
Higher than 7% of US stocks
Higher than 99% of US stocks
Higher than 18% of US stocks
Higher than 8% of US stocks
Higher than 13% of US stocks
Higher than 25% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ionis Pharmaceuticals, Inc. has a market value of $6.7B and an enterprise value of $6.9B.
Revenue in the twelve months to 30 June 2026: $874.1M. The latest quarter shrank 40.7% year on year.
Net income over the same four quarters: −$565.2M, a −64.7% net margin.
Diluted earnings per share, trailing twelve months: $−3.46.
Free cash flow in the twelve months to 30 June 2026: −$567.5M.
Trailing P/E: −17.0×; forward P/E: −35.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ionis Pharmaceuticals, Inc. employs 1,480 people — $591K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ionis Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ionis Pharmaceuticals announced it will host a live webcast on November 9 at 9:00 a.m. Eastern Time to discuss third quarter 2026 financial results and highlight progress on key programs. A limited-time replay will be available at the same webcast page.
Why it matters — IONS watchers can use the webcast to hear the company’s quarterly results and updates on key programs.
Zacks Investment Research previewed Ionis Pharmaceuticals’ upcoming Q3 report, saying the company lacks the combination of two key ingredients for a likely earnings beat. The item focuses on expectations ahead of the report.
Why it matters — IONS watchers may note the preview’s cautious assessment of the company’s prospects for an earnings beat.
Artisan Mid Cap Fund reported a negative absolute return in Q3 2026 while outperforming the Russell Midcap Growth Index. It ended its investment campaign in Ionis Pharmaceuticals during the quarter.
Why it matters — The fund’s decision to end its investment campaign in Ionis is relevant to IONS watchers as a reported portfolio change.
Seeking Alpha highlighted Ionis's independent launches as a growing source of commercial exposure, alongside recurring partner royalties. It also cited TRYNGOLZA's broader indication, DAWNZERA and ZANVASTRO, and HIBSAGO as contributors to revenue prospects and diversification.
Why it matters — The developments may expand Ionis's commercial reach and revenue sources while broadening its product and pipeline mix.
Roche, Ionis’s partner, reported Phase 3 IMAgINATION study data showing investigational sefaxersen reduced proteinuria by 43.1% in adults with primary IgA nephropathy receiving optimized standard of care. The reduction was statistically significant and described as clinically meaningful.
Why it matters — The results are relevant to IONS watchers because they provide clinical data on a program being developed with Ionis’s partner Roche.
The 25 Wall Street analysts covering Ionis Pharmaceuticals, Inc. have a median 12-month price target of $85, with estimates ranging from $58 to $105. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 25 analysts covering Ionis Pharmaceuticals, Inc., 21 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ionis Pharmaceuticals, Inc. 39 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Ionis Pharmaceuticals, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (89 of 100).
No one can know that. What the data says: the median 12-month target from 25 analysts implies +111.9% from the last close, and Ticker Nerd's factor model ranks Ionis Pharmaceuticals, Inc. 39 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ionis Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IONS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $58 to $105 over the next 12 months.
Ionis Pharmaceuticals, Inc. returned -45.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines.
The most recent item we track (Business Wire, 2 Nov 2026): "Ionis to hold third quarter 2026 financial results webcast". Ionis Pharmaceuticals announced it will host a live webcast on November 9 at 9:00 a.m. Eastern Time to discuss third quarter 2026 financial results and highlight progress on key programs. A limited-time replay will be available at the same webcast page.
Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines. Using its proprietary antisense technology, Ionis creates therapies designed to modulate gene expression and address serious diseases, particularly in neurology and cardiometabolic care, as well as other high-need therapeutic areas. The company currently markets several medicines for conditions such as spinal muscular atrophy, hereditary amyloidosis, amyotrophic lateral sclerosis, and certain rare cardiovascular and metabolic disorders. Ionis also maintains an active pipeline of investigational programs and collaborates with pharmaceutical partners to expand the reach of its platform. Headquartered in Carlsbad, California, Ionis Pharmaceuticals plays a significant role in the biotechnology market as a leading developer of RNA-based therapeutics.
CEO Dr. Brett P. Monia Ph.D. · 1,480 employees · United States · https://www.ionis.com
